Galapagos announces GSK2586184 JAK1 molecule moves into Phase 2 for ulcerative colitis
27 November 2013 - 5:48PM
Galapagos NV (Euronext: GLPG) announced today that
GlaxoSmithKline plan to initiate an exploratory Phase 2 study with
GSK2586184 (formerly GLPG0778) in patients with ulcerative colitis,
a third indication for this investigational molecule, in addition
to psoriasis and lupus.
GSK2586184 is a selective JAK1 inhibitor which
was discovered and developed within Galapagos' inflammation
alliance with GSK. GSK in-licensed the molecule in February 2012,
gaining worldwide rights to further development and
commercialization. Galapagos is eligible, without further
financial investment from Galapagos, to receive from GSK €34M in
additional milestones, plus up to double-digit royalties on global
commercial sales of all therapeutic indications of GSK2586184.
"Inhibition of Janus kinase (JAK) signalling
proteins is considered a promising new therapeutic route to treat
inflammatory diseases. Galapagos has discovered multiple JAK
inhibition molecules, three of which have reached the clinic," said
Onno van de Stolpe, CEO of Galapagos.
The Phase 2 studies with GSK2586184 in
ulcerative colitis, psoriasis, and lupus are scheduled to be
completed in November 2014, March 2014, and November 2015,
respectively. Further details of all three Phase 2 studies
can be found on www.gsk.com and www.clinicaltrials.gov, under
GSK2586184.
About ulcerative colitis Ulcerative colitis is
the most common inflammatory bowel disease worldwide. It is a
disease of the colon (large intestine) characterized by bloody
diarrhoea and there is often a disease pattern of gradual onset,
spontaneous remission and subsequent relapses. Symptoms of
frequent urgent diarrhoea, fatigue and abdominal pain can
significantly reduce a patient's quality of life and
productivity.
About Galapagos Galapagos (Euronext: GLPG; OTC:
GLPYY) is specialized in novel modes-of-action, with a large
pipeline comprising six Phase 2 studies (three led by GSK),
one Phase 1 study, five pre-clinical, and 20 discovery
small-molecule and antibody programs in cystic fibrosis,
inflammation, antibiotics, metabolic disease, and other
indications. AbbVie and Galapagos signed an agreement in CF where
they work collaboratively to develop and commercialize oral drugs
that address two mutations in the CFTR gene, the G551D and F508del
mutation. In the field of inflammation, AbbVie and Galapagos
signed a worldwide license agreement whereby AbbVie will be
responsible for further development and commercialization of
GLPG0634 after Phase 2B. GLPG0634 is an orally-available,
selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in
Phase 2B studies in RA and about to enter Phase 2 studies in
Crohn's disease. Galapagos has another selective JAK1
inhibitor in Phase 2 in lupus, psoriasis, and ulcerative colitis,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program is
currently in a Proof-of-Concept Phase 2 study. GLPG1205 is a
first-in-class molecule that targets inflammatory disorders and is
currently in a First-in-Human Phase 1 study. The Galapagos Group,
including fee-for-service companies BioFocus, Argenta and Fidelta,
has around 800 employees and operates facilities in five countries,
with global headquarters in Mechelen, Belgium. Further
information at: www.glpg.com
Contact
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240 ir@glpg.com
Galapagos forward-looking statements This
release may contain forward-looking statements, including, without
limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which
might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied by
such forward-looking statements. Given these uncertainties, the
reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak
only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
HUG#1745996
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jul 2023 to Jul 2024